Cox proportional hazard ratios ( HRs ) , adjusted for significant clinicopathologic risk factors , were used to determine the association of each gene with relapse-free survival ( RFS ) for 433 patients who received chemotherapy alone ( arm A ) and 849 patients who received chemotherapy plus trastuzumab ( arms B and C ) .